Pieris Pharmaceuticals Inc (PIRS) Expected to Announce Quarterly Sales of $6.69 Million
Brokerages predict that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce $6.69 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with the highest sales estimate coming in at $8.80 million and the lowest estimate coming in at $4.50 million. Pieris Pharmaceuticals reported sales of $18.15 million in the same quarter last year, which indicates a negative year-over-year growth rate of 63.1%. The business is expected to announce its next quarterly earnings results on Friday, March 8th.
According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year sales of $30.66 million for the current fiscal year, with estimates ranging from $28.70 million to $33.00 million. For the next fiscal year, analysts expect that the company will post sales of $22.74 million, with estimates ranging from $12.00 million to $31.00 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.04. The firm had revenue of $8.35 million for the quarter, compared to the consensus estimate of $6.16 million. Pieris Pharmaceuticals had a negative return on equity of 18.07% and a negative net margin of 17.90%.
In related news, Director Christopher P. Kiritsy bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The shares were bought at an average cost of $5.11 per share, with a total value of $25,550.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $51,100. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.07% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $110,000. Marshall Wace LLP bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $118,000. Fox Run Management L.L.C. bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $124,000. Bowling Portfolio Management LLC bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $156,000. Finally, California Public Employees Retirement System bought a new position in Pieris Pharmaceuticals in the 2nd quarter worth $179,000. 65.22% of the stock is currently owned by institutional investors.
Shares of PIRS stock traded up $0.07 on Monday, reaching $3.38. The stock had a trading volume of 444,532 shares, compared to its average volume of 607,637. The company has a market cap of $178.15 million, a P/E ratio of -8.45 and a beta of 1.94. Pieris Pharmaceuticals has a 1 year low of $3.04 and a 1 year high of $9.75.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
See Also: Cost of Capital Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.